
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
BioNTech's COVID-19 vaccine (co-developed with Pfizer) has made headlines with the announcement of its 90% efficacy rate. But this early data is subject to change and the vaccine must pass rigorous testing by the Therapeutic Goods Administration’s (TGA) before it's approved for use in Australia.
BioNTech SE is a German biotechnology company founded in 2008. BioNTech's COVID-19 vaccine (co-developed with Pfizer) propelled the company into the spotlight in 2020 with the announcement of its 90% efficacy rate. As one of the front runners in the development of a successful global vaccine, BioNTech's share price has since surged more than 600% by June 2021.
How to buy shares in BioNTech
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for BioNTech. Find the share by name or ticker symbol: BNTX. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BioNTech reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$134.04, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of BioNTech, depending on your broker.
- Check in on your investment. Congratulations, you own a part of BioNTech. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Our top pick for
US stocks

Our top pick for
Best Overall Broker

Our top pick for
Best low-cost broker

BioNTech stock price (NASDAQ:BNTX)
Use our graph to track the performance of BNTX stocks over time.BioNTech shares at a glance
52-week range | US$119.7341 - US$457.9346 |
---|---|
50-day moving average | US$153.4516 |
200-day moving average | US$214.8342 |
Target price | US$253.57 |
PE ratio | 2.4236 |
Dividend yield | US$0 (1.33%) |
Earnings per share (TTM) | US$51.635 |
Compare trading apps to buy BioNTech shares
Is it a good time to buy BioNTech stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
BioNTech price performance over time
Historical closes compared with the last close of $134.04
1 week (2022-06-17) | 7.11% |
---|---|
1 month (2022-05-26) | -15.25% |
3 months (2022-03-24) | -21.34% |
6 months (2021-12-23) | -47.50% |
1 year (2021-06-25) | -41.73% |
---|---|
2 years (2020-06-26) | 115.74% |
Stocks similar to BioNTech
Is BioNTech under- or over-valued?
Valuing BioNTech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioNTech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioNTech's P/E ratio
BioNTech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, BioNTech shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
BioNTech's PEG ratio
BioNTech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.0449. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioNTech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
BioNTech's EBITDA
BioNTech's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$17.8 billion (£14.5 billion).
The EBITDA is a measure of a BioNTech's overall financial performance and is widely used to measure a its profitability.
BioNTech financials
Revenue TTM | US$23.3 billion |
---|---|
Operating margin TTM | 75.98% |
Gross profit TTM | US$16.1 billion |
Return on assets TTM | 90.32% |
Return on equity TTM | 139.59% |
Profit margin | 55.2% |
Book value | 65.473 |
Market capitalisation | US$30.4 billion |
TTM: trailing 12 months
BioNTech share dividends
Dividend payout ratio: 3.95% of net profits
Recently BioNTech has paid out, on average, around 3.95% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.33% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), BioNTech shareholders could enjoy a 1.33% return on their shares, in the form of dividend payments. In BioNTech's case, that would currently equate to about $0 per share.
While BioNTech's payout ratio might seem low, this can signify that BioNTech is investing more in its future growth.
BioNTech's most recent dividend payout was on 17 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 2 June 2022 (the "ex-dividend date").
BioNTech share price volatility
Over the last 12 months, BioNTech's shares have ranged in value from as little as US$119.7341 up to US$457.9346. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioNTech's is -0.2923. This would suggest that BioNTech's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, BioNTech has bucked the trend.
BioNTech overview
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
BioNTech in the news
Pfizer's (PFE) Omicron-Based COVID Shot Betters Immune Response
No Government Money, No Problem for Moderna and Pfizer
Coronavirus tally: Pfizer says updated COVID-19 booster is better against omicron, as cases top 100,000 again
Frequently asked questions
More guides on Finder
-
How to buy Arcadia Minerals (AM7) shares
Steps to owning and managing Arcadia Minerals shares.
-
How to buy Nexgen Energy (NXG) shares
Steps to owning and managing Nexgen Energy shares.
-
How to buy Keypath Education (KED) shares
Steps to owning and managing Keypath Education shares.
-
What are green bonds and how do they impact the world?
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
-
5 best ways to invest money in Australia in 2022
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
-
How to buy EBR Systems (EBR) shares
Steps to owning and managing EBR Systems shares.
-
How to buy 5E Advanced Materials (5EA) shares
Steps to owning and managing 5E Advanced Materials shares.
-
How to buy Leo lithium shares
Steps to owning and managing Leo lithium shares.
-
How to buy Besra Gold (BEZ) shares
Steps to owning and managing Besra Gold shares.
-
How to buy The Lottery Corporation (TLC) shares
Steps to owning and managing The Lottery Corporation shares.
Ask an Expert